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Synthetic cannabinoids are man-made mind-alternating chemicals. Law 
enforcement and legislation have attempted to classify many of these synthetic 
cannabinoids as schedule I controlled substances, however, they are continuously being 
modified by dealers at the retail end of the distribution chain. Addiction and moderate use 
of illicit drugs have been identified as major reasons for non-adherence to antiretroviral 
therapy among HIV patients. However, there is no data regarding the impact of synthetic 
cannabinoid exposure in this population and how this affects their compliancy with 
taking antiretroviral therapy. A total of 72 authentic urine specimens were collected 
weekly from 13 individuals with HIV from Boom! Health Inc. (Bronx, New York City) 
over a 12-week period. We developed and validated an analytical method for the 
determination of 24 synthetic cannabinoids and metabolites in these urine samples. Out 
of 72 urine samples, 4 tested positive for AB-FUBINACA, UR-144 5-Pentanoic Acid, 
UR-144 4-Hydroxypentyl, 5-Fluoro-PB 22 and PB-22 at concentrations that ranged from 
1.41-8.93 ng/mL. The urine samples were also screened by immunoassay (EMIT) and 
GC-MS. The most common drugs detected were THC, cocaine, opiates, more specifically 
methadone and JWH-033. A preliminary LC-MSMS screening for new synthetic 
cannabinoids tested mainly positive for THJ-2201, AM2201 and ADB-FUBINACA. For 
the future of this research, the impact of synthetic cannabinoids on antiretroviral therapy 
discontinuation will be explored comparing urine results with self-report, as well as the 
differences in biological matrices (urine and oral fluid) for monitoring synthetic 
cannabinoids and classic drugs of abuse. 
 v 
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 Synthetic Psychoactive Drugs (SPDs) is a catch-all term that includes a 
wide range of drugs which have been available in the US for decades, but in recent years, 
new types, the so-called novel psychoactive substances (NPS), have emerged in the 
market and their use has rapidly grown problematic among particular subpopulations. 
NPS are a heterogeneous group of newly synthesized compounds that mimic classic drug 
effects (cocaine, amphetamines, cannabis, MDMA, heroin), but are pharmacologically 
more potent and with unknown short and long-term effects. These drugs are easy to 
obtain (smart shops, internet) and many of them are “legal” (not scheduled substances). 
Among NPS, synthetic cannabinoids (SC) (known colloquially as “K2”) are the most 
prevalent group.  
SC are man-made mind-altering chemicals created to mimic cannabis. They are 
normally sprayed on plant material and are falsely advertised in convenience stores as 
herbal incenses and air fresheners. They may also be sold as liquids that are smoked in 
vaporizers. These drugs have no medical benefit which has lead to classifying many of 
them as a schedule I controlled substance; however, NPS chemical structures are 
continuously modified by dealers at the retail end of the distribution chain in response to 
legislation and law enforcement efforts to make them less available (NIDA, 2015). For 
users, it has the additional benefit of making these novel compounds and their 
metabolites not easily detected by routine screening and confirmation tools in the 
laboratory. Many laboratories are using mass spectrometric screening methods as an 
alternate source to immunoassay methods (Heikman et al., 2016). In New York City, 
NPS, in particular SC, have become especially popular with some homeless people and 
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those who are subject to drug testing (like people living in supervised residences for 
mental health or substance use problems, active duty armed service members, and people 
on parole and probation).  
Although SC act on the same cell receptors (CB1 and CB2) as delta-9-
tetrahydrocannabinol (THC), they are actually much more potent than THC and have 
effects that are unpredictable and life threatening (Behonick et al., 2014). Current 
evidence suggests that SC pose a greater risk to user health than cannabis (Fantegrossi et 
al., 2014). It is also noteworthy that SC users have typically experimented with a wider 
variety of drugs than non-SC users and that they co-ingest SC along with other 
substances that may be problematic, but not thoroughly explored (Bonar et al., 2014).  
A wide range of symptoms have been associated with SC use and have been 
reported in the media, including psychotic episodes, paranoia, increased anxiety and 
hallucinations, increased heart rate, agitation, vomiting, seizures, uncontrollable body 
movements, lack of emotional attachment, sweating, loss of control, red eyes, dry mouth, 
and many others. Symptoms that some K2 users exhibit or experience may be the 
outcome of several factors. For example, the chemical content of the substance may 
change over time as dealers attempt to avoid the law, and these changes to the 
composition of the bags offered for retail sale may produce dramatically different effects 
among users (NIDA, 2015). Still more variation in the symptoms exhibited by NPS users 
may be the product of interaction effects with other drugs that they may use, like alcohol, 
cocaine, amphetamines, heroin or any number of pharmaceutical products. Most of the 
K2 exposures are based on self-report, but the actual toxicological information about the 
specific compounds involved in these cases, the concentrations detected in biological 
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specimens, how these concentrations correlate with the clinical outcome, and their 
combination with other drugs is scarce.  
Addiction and moderate use of illicit drugs have been identified as major reasons 
for non-adherence to antiretroviral therapy among HIV patients. However, there is no 
information about the impact of K2 exposure in this population and how this affects their 
adherence to antiretroviral therapy.  
The objective of this study was to monitor SC and drugs of abuse exposure in 
HIV-infected individuals following antiretroviral therapy. We developed and validated an 
analytical method for the determination of 11 SC (A-796260, AB-FUBINACA, AB-
PINACA, 5-Fluoro PB-22, JWH-018, JWH-073, XLR-11, UR-144, PB-22, APINACA 
(AKB-48), and MAM2201) and 13 metabolites (AB-PINACA 5-Pentanoic acid, JWH-
018 5-Pentanoic acid, JWH-073 4-Butanoic acid, JWH-250 4-Hydroxypentyl, AM2201 
4-Hydroxypentyl, JWH-019 5-Hydroxyhexyl, JWH-122 4-Hydroxypentyl, UR-144 5-
Pentanoic acid, XLR-11 4-Hydroxypentyl, UR-144 4-Hydroxypentyl, MAM2201 4-
Hydroxypentyl, APINACA (AKB-48) 5-Hydroxypentyl, JWH-210 4-Hydroxypentyl) in 
urine samples, and we screened these samples for new SC and classic drugs of abuse.   
2. Methods 
2.1 Reagents and supplies 
 All standards (A-796260, AB-PINACA 5-Pentanoic acid, AB-FUBINACA, AB-
PINACA, JWH-018 5-Pentanoic acid, JWH-073 4-Butanoic acid, JWH-250 4-
Hydroxypentyl, AM2201 4-Hydroxypentyl, 5-Fluoro PB-22, JWH-019 5-Hydroxyhexyl, 
JWH-122 4-Hydroxypentyl, UR-144 5-Pentanoic acid, XLR-11 4-Hydroxypentyl, UR-
144 4-Hydroxypentyl, MAM2201 4-Hydroxypentyl, APINACA (AKB-48) 5-
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Hydroxypentyl, JWH-210 4-Hydroxypentyl, JWH-018, JWH-073, XLR-11, UR-144, PB-
22, APINACA (AKB-48), and MAM2201) and internal standards (JWH-250 4-
Hydroxypentyl-D5, AM2201 4-Hydroxypentyl-D5, and JWH-210 4-Hydroxypentyl-D5) 
were purchased from Cerilliant (Round Rock, TX). Ammonium acetate, acetic acid, 
acetonitrile, ethyl acetate, methanol were obtained from Pharmco-Apper (Brookfield, 
CT), and formic acid from Fisher Scientific (Fair Lawn, NJ). Water was purified by an 
ELGA Purelab Ultra Analytic purifier (Siemens Water Tech, Lowell, MA). All solvents 
were HPLC or better. Abalone beta-glucuronidase containing 100,000 units/mL was 
purchased from Campbell Science (Rockford, IL). 1mL Isolute SLE+ cartridges were 
utilized for preparing samples from Biotage, Inc. (Charlotte, NC). A Restrep 24-port SPE 
manifold (Restek Inc., Bellefonte, PA) was used for specimen extraction. A Kinetex C18 
column (100 x 2.1 mm) combined with a guard column with the same chemistry (10 x 2.1 
mm) was purchased from Phenomenex Inc. (Torrance, CA) and was used for analytical 
chromatography. During method development a Kinetex F5 column (100 x 2.1 mm) 
combined with a guard column (10 x 2.1 mm), as well as Novum SLE+ cartridges 
utilized for preparing samples were explored and acquired from Phenomenex Inc. 
2.2 Sample collection and storage 
 A total of 72 authentic urine specimens were collected from 13 individuals from 
Boom! Health Inc. (Bronx, New York City) weekly, over a 12-week period. The 
participants provided written informed consent to participate in this study. The study was 
approved by The City University of New York IRB. Urine specimens were collected by 
the participants in FisherbrandTM 4 oz. polypropylene specimen containers (Fisher 
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Scientifc, Waltham, MA), aliquoted in 2 mL polypropylene cryotubes (Fisher Scientific) 
and stored in the freezer at -20° C until analysis. 
2.3 Synthetic Cannabinoids Confirmatory Method 
2.3.1. Instrumentation 
 A Shimadzu (Columbia, MD) ultra high performance liquid chromatography 
tandem mass spectrometer (UHPLC-MS/MS) LCMS-8030, equipped with a Shimadzu 
Nexera X2 LC-30AD ultra high performance liquid chromatograph (UHPLC) coupled to 
an electrospray and atmospheric-pressure chemical ionization (ESI/APCI) dual probe 
ionization source and a triple quadrupole mass spectrometer was employed.  
2.3.2. Calibrators, quality control and internal standards 
 Stock solutions of each synthetic cannabinoid (11 parent compounds and 13 
metabolites) were created in methanol or acetontrile at concentrations of 10 µg/mL. 
Dilutions of the stock solutions created working solutions containing all 24 SC in 
methanol at concentrations 5, 50, 100, and 400 ng/mL. Blank urine from healthy 
volunteers was then fortified with the working solutions to create calibrators and quality 
control samples at concentrations 1, 5, 10, 15, 20, 40, 50 and 100 ng/mL (see Table 1). 
Table 1: Calibrators and quality controls sample preparation. Volume of working 
solutions employed to fortify blank urine samples to yield calibrators and quality controls 
at concentrations 1 to 100 ng/mL. 
Working Solutions Calibrators/ 
Quality Controls 5 ng/mL 50 ng/mL 100 ng/mL 400 ng/mL 
1 ng/mL 40 uL - - - 
5 ng/mL - 20 uL - - 
10 ng/mL - - 20 uL - 
QC 15 ng/mL - - 30 uL - 
20 ng/mL - - 40 uL - 
40 ng/mL - - 80 uL - 
QC 50 ng/mL - - - 25 uL 
100 ng/mL - - - 50 uL 




- - 50 uL - 
  
 Each deuterated internal standard stock solution was created in methanol at a 
concentration of 10 µg/mL. A working solution containing all three of the internal 
standards was prepared at 0.1 µg/mL in methanol. All stock solutions and working 
solutions were stored at -20° in amber vials. 
2.3.3 Specimen extraction  
 Sample extraction followed the protocol described by Scheidweiler and Huestis 
(Scheidweiler & Huestis, 2014). For preparation, 200 µL of blank urine was placed into 
polyproplyene microcentrifuge tubes, followed by 50 µL of the internal standard mix. 
This was diluted with 0.3 mL of 400 mM ammonium acetate buffer, pH 4.0, prior to the 
addition of 40 µL of glucuronidase solution (100,000 units glucuronidase activity/mL). 
The polyproplyene microcentrifuge tubes were then capped and incubated at 55°C for 2 
hours. Five hundred µL of acetonitrile was added and then the samples were centrifuged 
at 6,500 rpm at 4°C for 5 minutes. The supernatant was then transferred onto the Biotage 
SLE columns and driven onto the column phase with slight pressure. After keeping 
equilibrium at constant pressure for 5 minutes, analytes were eluted with 6 mL of ethyl 
acetate into polyproplyene microcentrifuge tubes. Pressure was applied for 5 minutes 
until elution was complete. All samples were completely dried at 45°C under nitrogen in 
a Biotage TurboVap. Samples were reconstituted in 150 µL mobile phase A:B, 85:15 
(v/v), vortexed for 15 seconds prior to centrifugation at 4°C at 6,500 rpm for 5 minutes 
and then transferred to autosampler vials containing 300 µL inserts. Mobile phase (A) 
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consisted of 0. 1% formic acid in UHP water and mobile phase (B) consisted of 0. 1% 
formic acid in acetonitrile. 
2.3.4. LC-MS/MS 
 Chromatographic separation was performed on a Kinetex C18 column with an 
attached guard column containing the same packing material. A 12-minute positive 
ionization method with a 20 µL injection volume was performed each time samples or 
standards were injected. Gradient elution was performed with two mobile phases (A, 0. 
1% formic acid in UHP water, and B, 0. 1% formic acid in acetonitrile), a flow rate of 0.4 
mL/min and initial column oven temperature at 35°C. The initial conditions of the 
gradient were 15% B, held for 2.5 minutes, increased to 50% by 2.5 minutes, and then 
increased again to 60% by 5.75 minutes. It was then increased to 95% B by 6.75 minutes 
and held at 95% until 9.0 minutes. It was then returned to 15% B by 9.5 minutes and held 
at 15% until 12 minutes was reached. 
 The mass spectrometric data was collected in scheduled multiple reaction-
monitoring (MRM) mode. The MRM windows were 1 to 3.5 minutes, 3.5 to 4.75 
minutes, 4.75 to 6.5 minutes, and 6.5 minutes to 9 minutes. Respectively, in the first 
MRM window compounds: A-796260, and AB-PINACA 5-Pentanoic acid were 
monitored. In the second MRM window: AB-FUBINACA, AB-PINACA, JWH-018 5-
Pentanoic acid, JWH-073 4-Butanoic acid, JWH-250 4-Hydroxypentyl, AM2201 4-
Hydroxypentyl, JWH-250 4-Hydroxypentyl-D5, and AM2201 4-Hydroxypentyl-D5 were 
monitored. In the third MRM window, the compounds: 5-Fluoro PB-22, JWH-019 5-
Hydroxyhexyl, JWH-122 4-Hydroxypentyl, UR-144 5-Pentanoic acid, XLR-11 4-
Hydroxypentyl, UR-144 4-Hydroxypentyl, MAM2201 4-Hydroxypentyl, JWH-210 4-
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Hydroxypentyl-D5, APINACA (AKB-48) 5-Hydroxypentyl, and JWH-210 4-
Hydroxypentyl were monitored. In the last MRM window, the compounds: JWH-018, 
JWH-073, XLR-11, UR-144, PB-22, APINACA (AKB-48), and MAM2201 were 
monitored. These analytes were optimized by individually injecting 2 µL at a 
concentration of 1 µg/mL. Quantifier and qualifier ion transitions were monitored for 
each analyte and internal standard (see Table 2). 
Table 2: Liquid chromatography-tandem mass spectrometry parameters for synthetic 






Product (m/z) Q1 (V) CE Q3 (V) Retention 
Time 
(min) 
JWH-018 22 341.8 126.95, 154.95 -22, -22 -48, -27 -26, -30 7.392 
JWH-073 20 327.8 127, 154.9 -21, -21 -50, -24 -27, -11 7.144 
XLR-11 21 330 55.1, 125 -15, -15 -46, -26 -22, -27 7.202 
UR-144 23 311.9 54.95, 124.90 -13, -13 -43, -24 -22, -27 7.610 
A-796260 2 355.1 114.1, 125 -17, -17 -32, -24 -23, -26 3.102 
AB-
FUBINACA 
3 369 109.05, 253.05 -10, -10 -45, -27 -22, -18 3.731 
5-Fluoro PB-
22 
15 377 143.85, 232.10 -25, -25 -42, -16 -15, -17 5.522 
PB-22 18 358.8 143.95, 214 -16, -16 -37, -17 -15, -10 6.927 
AB-PINACA 6 331 144.95, 215.10 -15, -15 -42, -26 -15, -25 4.192 
APINACA 
(AKB-48) 
24 366.1 135.1, 93.15 -10, -10 -24, -54 -14, -18 7.951 
MAM2201 19 373.8 141.05, 168.95 -16, -16 -45, -29 -29, -18 7.090 
JWH-018 5-
Pentanoic acid 
7 372 126.9, 154.85 -10, -10 -49, -24 -13, -17 4.351 
JWH-073 4-
Butanoic acid 
5 358 126.95, 154.95 -10, -10 -49, -23 -27,-16 4.111 
JWH-019 5-
Hydroxyhexyl 
10 372 127, 154.95 -10, -10 -49, -25 -26, -30 4.984 
JWH-250 4-
Hydroxypentyl 
4 351.80 91.15, 121 -22, -22 -55, -25 -19, -26 4.006 
JWH-122 4-
Hydroxypentyl 
12 372 140.95, 169.05 -10, -10 -47, -24 -29, -18 5.060 
JWH 210 4-
Hydroxypentyl 
16 386.1 154.9, 183 -10, -10 -40, -26 -29, -20 5.664 
AM2201 4-
Hydroxypentyl 




11 342 55.1, 125 -15, -15 -45, -24 -23, -28 4.987 
XLR-11 4-
Hydroxypentyl 








17 382.1 79, 135.15 -18, -18 -55, -27 -16, -29 5.822 
UR-144 4-
Hydroxypentyl 
14 328.1 55, 125.05 -30, -30 -44, -22 -22, -26 5.271 
MAM2201 4-
Hydroxypentyl 












16 390.9 154.9, 183 -13, -13 -44, -29 -11, -19 5.664 
 
2.3.5. Method validation  
 Method validation was completed for the following categories: linearity, limit of 
detection, limit of quantification, accuracy and imprecision, extraction efficiency, matrix 
effect, and process efficiency by procedures described by the Scientific Working Group 
for Forensic Toxicology (SWGTOX, 2013).  
Linearity, limit of detection, limit of quantification 
 Linearity was completed over five days using least squares regression with 1/x2 
weighing factor. If the coefficient of determination (r2) was greater than 0.99 and 
residuals were < 20%, satisfactory linearity was accomplished. Limit of detection (LOD) 
and limit of quantification (LOQ) were determined by injecting fortified samples with 
decreasing analyte concentrations. The LOD had a signal to noise ratio that was greater 
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than 3, had the presence of all product ions, correct ion ratio, and a retention time within 
±0.2 minutes of the calibrator retention time. The LOQ was satisfied when the lowest 
concentration had imprecision less then ±20% and an accuracy of 80-120%. 
Accuracy and imprecision 
 Intra-day and inter-day accuracy, and imprecision were determined from three 
replicates at two different quality control concentrations (15 and 50 ng/mL) within the 
dynamic range of the calibration curve over five days. Intra-day and inter-day accuracy 
was determined by how close the result averages were to that specific quality control 
concentration. The values were expected to be within 80-120%. Intra-day and inter-day 
imprecision was calculated by the coefficient of variation and was expected to be less 
than 20%. 
Extraction efficiency, matrix effect and process efficiency 
 Three sets of samples were prepared, and all samples were prepared at a 
concentration of 15 ng/mL. Set one was prepared by creating three neat samples. 
Standards and internal standards were evaporated and reconstituted with mobile phase. 
Set two was prepared by taking ten different blank urine samples, running them through 
the SLE procedure and then fortifying them with the standards and internal standards 
directly before evaporation. Set three was prepared by taking five different blank urines, 
fortified them with the corresponding standard and internal standard solutions, and 
running them through the normal procedure for authentic samples. In order to determine 
the extraction efficiency, set two and set three were compared. In order to determine if 
there were any matrix effects set one and set two were compared and lastly, in order to 
determine the process efficiency set one and set three were compared.  
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Identification Criteria 
 In order to confirm if a synthetic cannabinoid was present using the LC-MSMS 
several factors must be considered. Firstly, the retention time of the synthetic cannabinoid 
must be within ±0.2 minutes of the calibrator retention time. Secondly, both the quantifier 
and qualifier product ion must be present and lastly, the ion ratio between the qualifier 
and quantifier product ion must be within ±20% of the calibrators’ ion ratio average. 
2.4 Screening methods  
 Urine samples were submitted to 3 screening methods. An immunoassay method 
to detect classic drugs of abuse, a general unknown screening method by GC-MS and a 
screening method for new emerging SC by LC-MSMS. 
 The urine samples were screened for tetrahydrocannabinol (THC), amphetamines, 
barbiturates, benzodiazepines, cocaine, and opiates by the enzyme multiplied 
immunoassay technique Viva-Jr (EMIT) from Siemens Healthineers Global (Erlangen, 
Germany). To accomplish this, 500 µL of each authentic urine sample was placed into 
small plastic cups. The information for each sample was entered under ‘order samples’ 
and the drugs that were to be tested for were checked. The samples were then loaded onto 
the outer rotor in their assigned positions. 
 Urine samples were also submitted to a general unknown screening by gas 
chromatography-electron impact-mass spectrometry-QP2010 (GC-MS) from Shimadzu 
(Columbia, MD). From each day authentic samples were run for SC confirmation by LC-
MSMS, 100 uL of each urine sample, 100 uL of one of the 50 ng/mL quality control and 
100 uL of the 100 ng/mL calibrator extracts were taken out of the LC-MSMS vials and 
were placed in separate polyproplyene microcentrifuge tubes, evaporated in the 
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TurboVap under nitrogen at 50°C for 25 minutes and then reconstituted in 100 µL of 
methanol. They then were placed into new vials and subjected to the GC-MS method that 
scanned for the presence of any analyte over a 20-minute period monitoring 50-600 m/z. 
The gradient used for this method started at 85°C and was held for one minute, increased 
15°C until 145°C was reached and then increased 35°C until the final temperature of 
285°C was achieved. This temperature was then held out for 11 minutes. Data analysis 
was performed using the SWGDRUG library. 
 The extracted urine samples were also re-injected in the LC-MSMS by a 
screening method to detect additional SC, for which reference standards were not 
available. The chromatographic separation was the same as that for the confirmatory LC-
MSMS separation and the MS mode was set to scan between 100 to 600 m/z. Data 
analysis was performed extracting the m/z of the pseudomolecular ion (molecular weight 
+ 1) of 18 newly discovered SC: NM2201, MMB-CHMICA, MDMB-FUBINACA, 
JWH-081, FUB-AK848 AM2201, ADB-FUBINACA, AB-CHMINACA, 5F-AB-
PINACA, THJ-2201, JWH-122, JWH-250, JWH-019, 5F-AMB, JWH-073, JWH-018, 
5F-MDMB-PINACA, and FUB-AMB. 
3. Results 
3.1 Chromatography 
 Chromatographic or/and mass resolution between all analytes was possible (see 
Figure 1); retention times did not drift more than ±0.2 minutes. 
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Figure 1: Total ion chromatogram of synthetic cannabinoids, metabolites, and internal 
standards in urine at a concentration of 100 ng/mL 
 
3.2 Method Validation 
Linearity, limit of detection, limit of quantification 
 All SC had a limit of detection and limit of quantification of 1 ng/mL. The 
linearity of the SC and metabolites was from 1-100 ng/mL (see Table 3). 
Table 3:  Synthetic cannabinoids and metabolites in human urine by liquid 
chromatography-tandem mass spectrometry calibration results (N=5), the limit of 
detection for all compounds was 1 ng/mL, and the linear range for all compounds was 1-
100 ng/mL 






























































PB-22 JWH-210 4- 0.001611057 0.731283 0.99053004 
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Accuracy and imprecision 
 The intra-day imprecision and accuracy for the synthetic cannabinoid metabolites 
was 1.0-14.6% and 83.3-105.5% respectively. For inter-day, the results for imprecision 
and accuracy was as follows: 3.3-10.5% and 84.9-103.8%. In the case of the synthetic 
cannabinoid parent compounds, the intra-day imprecision and accuracy was 5.4-91.1% 
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and 48.3-122.1% respectively. For inter-day, the results for imprecision and accuracy was 
as follows: 5.3-85.4% and 73.9-102.7%  (see Table 4). 
Table 4: Analytical accuracy and imprecision data for synthetic cannabinoids and 
metabolites at quality controls 15 and 50 ng/mL in human urine by liquid 
chromatography-tandem mass spectrometry 










15 50 15 50 15 50 15 50 
JWH-018 30.6 41.6 32.1 62.9 94.8 74.5 103.7 66.9 
JWH-073 15.3 27.3 13.0 43.8 97.6 86.4 107.2 93.1 
XLR-11 11.5 17.8 7.6 26.2 94.3 84.5 98.0 89.3 
UR-144 44.2 53.3 43.4 77.6 96.9 73.9 122.1 70.9 
A-796260 5.3 8.4 0.7 11.2 97.1 100.6 93.1 100.1 
AB-
FUBINACA 
6.8 6.6 5.4 7.0 96.9 102.6 90.3 100.9 
5-Fluoro PB-22 26.3 9.8 26.3 9.8 95.6 102.0 96.2 92.0 
PB-22 12.2 18.5 15.6 31.5 102.2 89.6 115.7 94.6 
AB-PINACA 8.7 7.6 11.0 15.5 97.2 102.7 86.6 99.8 
APINACA 
(AKB-48) 
71.7 85.4 50.4 91.1 89.7 79.1 119.0 48.3 
MAM2201 12.8 24.3 10.5 14.4 95.5 84.9 101.8 80.4 
JWH-018 5-
Pentanoic acid 
8.5 7.7 4.7 1.4 96.1 101.4 83.3 92.5 
JWH-073 4-
Butanoic acid 
7.3 6.3 4.3 2.5 97.5 102.0 87.3 94.2 
JWH-019 5-
Hydroxyhexyl 
6.8 7.1 3.9 4.8 98.1 102.1 89.0 95.3 
JWH-250 4-
Hydroxypentyl 
5.5 5.1 2.8 2.0 98.9 101.2 93.4 97.7 
JWH-122 4-
Hydroxypentyl 
9.8 8.2 6.6 8.2 98.6 103.8 92.7 101.7 
JWH 210 4-
Hydroxypentyl 
3.3 3.9 1.5 1.0 98.8 100.6 95.0 96.3 
AM2201 4-
Hydroxypentyl 
4.5 5.5 2.4 3.0 99.4 102.0 94.5 100.6 
UR-144 5-
Pentanoic acid 
5.2 7.5 5.7 8.1 100.7 101.6 94.7 93.5 
XLR-11 4-
Hydroxypentyl 




5.6 8.0 4.3 4.2 99.1 98.2 94.8 87.4 






6.3 8.7 5.6 14.6 99.2 98.3 92.6 92.6 
MAM2201 4-
Hydroxypentyl 
6.7 10.5 6.6 3.5 98.4 103.5 88.8 95.9 
 
Extraction efficiency, matrix effect, and process efficiency 
 For synthetic cannabinoid metabolites, the extraction efficiencies were from 83.2-
107.4%, matrix effects from -22 to -41.7%, and process efficiencies from 60.7-104.9%. 
For synthetic cannabinoid parent compounds, the extraction efficiencies were from 42-
98.4%, matrix effects from -11.9 to -65.3%, and process efficiencies were from 23.1-
86.7% (see Table 5). 
Table 5: Mean extraction efficiencies, matrix efficiencies and process efficiencies for 
synthetic cannabinoids and metabolites at quality control 15 ng/mL extracted from urine 
by supported-liquid extraction 
Analyte Extraction 
Efficiency 
Matrix Efficiency Process Efficiency 
JWH-018 59.9 -57.1 25.7 
JWH-073 53.5 -56.8 23.1 
XLR-11 47.3 -51.1 23.2 
UR-144 42.0 -26.7 30.8 
A-796260 90.7 -46.6 48.5 
AB-FUBINACA 93.9 -42.3 54.2 
5-Fluoro PB-22 77.6 -27.4 56.4 
PB-22 91.2 -65.3 31.6 
AB-PINACA 98.4 -11.9 86.7 
APINACA (AKB-48) 89.7 -13.0 78.1 
MAM2201 83.9 -57.5 35.7 
JWH-018 5-Pentanoic 
acid 
95.6 -22.7 73.9 
JWH-073 4-Butanoic 
acid 
94.8 -8.9 86.4 
JWH-019 5-
Hydroxyhexyl 
100.7 -25.7 74.9 
JWH-250 4-
Hydroxypentyl 
95.0 -36.1 60.8 
JWH-122 4-
Hydroxypentyl 




107.4 -40.9 63.5 
AM2201 4-
Hydroxypentyl 
97.0 -22.2 75.5 
UR-144 5-Pentanoic 
acid 
102.5 -37.1 64.5 
XLR-11 4-
Hydroxypentyl 
101.7 -32.3 68.8 
AB-PINACA 5-
Pentanoic acid 
83.2 26.1 104.9 
APINACA (AKB-48) 
5-Hydroxypentyl 
105.7 -28.9 75.1 
UR-144 4-
Hydroxypentyl 
104.0 -41.7 60.7 
MAM2201 4-
Hydroxypentyl 
90.7 -23.6 69.3 
 
3.3 Authentic urine samples analysis
This method was applied to the measurement of SC and metabolites from the 72 
authentic urine samples. From these authentic urine samples, 4 tested positive and were 
collected from 3 different participants. The SC and metabolites detected were AB-
FUBINACA (3.02 ng/mL), UR-144 Pentanoic Acid (2.97-8.93 ng/mL), UR-144 4-
Hydroxypentyl (1.71 ng/mL), 5-Fluoro PB-22 (1.41 ng/mL), and PB-22 (1.41 ng/mL). 
See Table 6. Figure 2 shows a chromatogram of an authentic urine sample positive for 
UR-144 5-Pentanoic Acid. 
Table 6: Authentic urine results positive for synthetic cannabinoids and metabolites 
Sample ID Collection Date Synthetic Cannabinoid (+) Concentration 
(ng/mL) 
CSG7410451 15-Jun-2016 AB-FUBINACA 3.02 




GLG8010451 13-Jul-2016 UR-144 5-Pentanoic Acid 2.97 






Figure 2: Individual GLG8010451 showing positive result (2.97 ng/mL) for UR-144 5-
Pentanoic Acid 
 
3.4 Screening methods 
 From the EMIT screening, 25 urine samples tested positive for opiates; 36 tested 
positive for cocaine; 23 tested positive for benzodiazepines, and 40 tested positive for 
THC. As for the other two drugs on the panel, barbiturates and amphetamines, all 72 
cases came back negative (see Table 7). 
Table 7: EMIT screening results  (N=72) 








 After analyzing the general unknown GC-MS screening, 45 urine samples 
screened positive for methadone; 44 urine samples screened positive for JWH-033; 1 
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urine sample screened positive for cyclobarbital; 1 urine sample screened positive for 
venlafaxine; 4 urine samples screened positive for gabapentin (see Figure 3,4); 2 urine 
samples screened positive for buphedrone metabolite; 2 urine samples screened positive 
for cocaine; 1 urine sample screened positive for methylephedrine; 4 urine samples 
screened positive for mirtazephine, and 1 urine sample tested positive for 
diphenhydramine (see Table 8). 
Table 8: GC-MS screening results (N=72) 













Figure 3: Chromatogram of individual GLG8010451 from GCMS screening 
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Figure 4: Library search of peak 1 from chromatogram of individual GLG8010451 
(Figure 3) showing positive GCMS screening result for gabapentin  
 After attempting to detect additional new SC with the LC-MSMS screening, 60 
urine samples screened positive for NM2201; 13 urine samples screened positive for 
MMB-CHMICA; 6 urine samples screened positive for MDMB-FUBINACA and JWH-
081; 60 urine samples screened positive for AM2201; 65 urine samples screened positive 
for ADB-FUBINACA; 46 urine samples screened positive for AB-CHMINACA; 4 urine 
samples screened positive for 5F-AB-PINACA; 56 urine samples screened positive for 
JWH-250; 1 urine samples screened positive for 5F-AMB; 43 urine samples screened 
positive for JWH-018; 33 urine samples screened positive for 5F-MDMB-PINACA; and 
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11 urine samples screened positive for FUB-AMB. All 72 urine samples screened 
positive for THJ-2201 (see Figure 5), while no urine samples screened positive for FUB-
AK848, JWH-122, JWH-019, and JWH-073 (see Table 9). 
Table 9: LC-MSMS screening results (N=72) 
Synthetic Cannabinoid Molecular Weight Number of Cases Screened Positive 
NM2201 376 60 
MMB-CHMICA 371 13 
MDMB-FUBINACA 372 6 
JWH-081 372 6 
FUB-AK848 404 0 
AM2201 360 69 
ADB-FUBINACA 383 65 
AB-CHMINACA 357 46 
5F-AB-PINACA 349 4 
THJ-2201 361 72 
JWH-122 356 0 
JWH-250 336 56 
JWH-019 356 0 
5F-AMB 364 1 
JWH-073 328 0 
JWH-018 342 43 
5F-MDMB-PINACA 378 33 
FUB-AMB 384 11 
 
 
Figure 5: Extracted chromatogram of individual F74722015SW from LC-MSMS 
screening showing positive result for THJ-2201 
4. Discussion 
There have been a number of methods published in order to determine SC and 
their metabolites in urine, (Scheildweiler et al., 2015; Ozturk, et al., 2015; Bertol et al., 
2015; Castaneto et al., 2105; Jang et al., 2015; Hutter et al., 2012), and there have been 
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numerous methods for the determination of drugs of abuse and their non-adherence to 
antiretroviral therapy (Moore et al., 2012; Hosseini et al., 2106; Cohn et al., 2011). 
However, there is limited evidence on how the exposure to these new NPS called SC 
correlates with HIV-infected patients and their adherence to antiretroviral therapy. 
By developing and validating an analytical method for the determination of 11 SC 
(A-796260, AB-FUBINACA, AB-PINACA, 5-Fluoro PB-22, JWH-018, JWH-073, 
XLR-11, UR-144, PB-22, APINACA (AKB-48), and MAM2201) and 13 metabolites 
(AB-PINACA 5-Pentanoic acid, JWH-018 5-Pentanoic acid, JWH-073 4-Butanoic acid, 
JWH-250 4-Hydroxypentyl, AM2201 4-Hydroxypentyl, JWH-019 5-Hydroxyhexyl, 
JWH-122 4-Hydroxypentyl, UR-144 5-Pentanoic acid, XLR-11 4-Hydroxypentyl, UR-
144 4-Hydroxypentyl, MAM2201 4-Hydroxypentyl, APINACA (AKB-48) 5-
Hydroxypentyl, JWH-210 4-Hydroxypentyl) in urine samples, an initial assessment can 
be conducted in order to see how well urine as a biological matrix for detecting SC would 
be. The parent drugs of SC were included in order to see what other information about 
recent intake could be observed, even though their metabolites are more predominantly 
detected in urine (Scheidweiler et al., 2014). However, due to the lack of standards of 
these SC, it was important to run a screening test with new SC that are currently 
emerging to see which of these are most popular amongst this population. As more 
standards become available, they easily can be introduced into the confirmatory method 
so a more accurate representation of what SC being taken can be accounted for. A 
screening test for other drugs of abuse was also conducted in order to see which other 
drugs were being taken solely or concurrently with the SC. 
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 Since Boom! Health Inc. is an organization that helps individuals and 
communities impacted by drug use, especially those with HIV, and since these 
individuals have admitted to drug use, positive results were expected. Three different 
individuals tested positive for the SC being monitored; one tested positive for different 
SC two weeks in a row. Due to the small amount of SC actually being monitored it is 
unclear whether or not the other individuals present in this study took SC that were not 
being monitored. Likewise, making screening for emerging SC important. It was rather 
alarming that 45 and 44 of the samples collected were screened positive for methadone 
and the synthetic cannabinoid JWH-033 respectively. In addition, many of these 
individuals screened positive for opiates, benzodiazepines, THC, and or cocaine. 
 Urine proved to be a decent biological matrix to test for synthetic cannabinoids 
achieving linearity and excellent accuracy and imprecision for all metabolites. The intra-
day imprecision and accuracy for the synthetic cannabinoid metabolites were 1.0-14.6% 
and 83.3-105.5% respectively. For inter-day, the results for imprecision and accuracy 
were as follows: 3.3-10.5% and 84.9-103.8%. Equally as impressive, extraction 
efficiencies ranged from 83.2-107.4%, matrix effects from -22 to -41.7%, and process 
efficiencies from 60.7-104.9%. Our research method was adapted from research done by 
Scheidweiler and Huetis (2014). They reported analytical recovery from 83.3 to 118.3% 
of expected concentrations for intra-day and inter-day analytical recoveries and intra-day 
and inter-day imprecision from 0.8–9.1 and 4.3–13.5%, respectively. They also reported 
mean extraction efficiencies of 43.7–109.3% (n = 10) and mean matrix effects of −73.1 to 
51.7%. Our results show slightly better accuracy, as well as less matrix effects and higher 
extraction efficiencies.  
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After conducting our validation, the imprecision was above the permitted range of 
20% for the synthetic cannabinoids: JWH-018, UR-144 and APINACA (AKB-48) for our 
research, and because of that these compounds can’t be quantified with this method. So, 
unfortunately, even though individual 3260122164 had a confirmed positive result of 
1.44 ng/mL of UR-144 present in their urine, it may not be considered a positive result. 
For the future of this research, the impact of SC on antiretroviral therapy 
discontinuation will be explored as well as the differences in biological matrices (urine 
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